The South African breast cancer and HIV outcomes study: Profiling the cancer centres and cohort characteristics, diagnostic pathways, and treatment approaches.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
07
2022
accepted:
31
08
2023
medline:
24
10
2023
pubmed:
24
10
2023
entrez:
24
10
2023
Statut:
epublish
Résumé
The South African Breast Cancer and HIV Outcomes prospective cohort (SABCHO) study was established to investigate survival determinants among HIV-positive and HIV-negative SA women with breast cancer. This paper describes common and unique characteristics of the cancer centres and their participants, examining disparities in pathways to diagnosis, treatment resources and approaches adopted to mitigate resource constraints. The Johannesburg (Jhb), Soweto (Sow), and Durban (Dbn) sites treat mainly urban, relatively better educated and more socioeconomically advantaged patients whereas the Pietermaritzburg (Pmb) and Empangeni (Emp) sites treat predominantly rural, less educated and more impoverished communities The Sow, Jhb, and Emp sites had relatively younger patients (mean ages 54 ±14.5, 55±13.7 and 54±14.3 respectively), whereas patients at the Dbn and Pmb sites, with greater representation of Asian Indian women, were relatively older (mean age 57 ±13.9 and 58 ±14.6 respectively). HIV prevalence among the cohort was high, ranging from 15%-42%, (Cohort obesity (BMI ≥ 30 kg/m2) at 60%, self-reported hypertension (41%) and diabetes (13%). Direct referral of patients from primary care clinics to cancer centre occurred only at the Sow site which uniquely ran an open clinic and where early stage (I and II) proportions were highest at 48.5%. The other sites relied on indirect patient referral from regional hospitals where significant delays in diagnostics occurred and early-stage proportions were a low (15%- 37.3%). The Emp site referred patients for all treatments to the Dbn site located 200km away; the Sow site provided surgery and endocrine treatment services but referred patients to the Jhb site 30 Km away for chemo- and radiation therapy. The Jhb, Dbn and Pmb sites all provided complete oncology treatment services. All treatment centres followed international guidelines for their treatment approaches. Findings may inform policy interventions to address national and regional disparities in breast cancer care.
Identifiants
pubmed: 37874786
doi: 10.1371/journal.pgph.0002432
pii: PGPH-D-22-01180
pmc: PMC10597516
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0002432Informations de copyright
Copyright: © 2023 Mapanga et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Infect Agent Cancer. 2017 Feb 14;12:13
pubmed: 28228841
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Cancer. 2021 May 1;148(9):2212-2226
pubmed: 33197280
Exp Biol Med (Maywood). 2021 Jun;246(12):1377-1387
pubmed: 33926257
Breast Care (Basel). 2015 Dec;10(6):364-70
pubmed: 26989354
J Glob Oncol. 2017 Apr;3(2):114-124
pubmed: 28706996
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
BMC Med. 2022 Feb 11;20(1):72
pubmed: 35151316
Oncologist. 2019 Jul;24(7):933-944
pubmed: 30518615
Int J Cancer. 2022 Jul 15;151(2):209-221
pubmed: 35218568
BMC Public Health. 2021 Jul 6;21(1):1325
pubmed: 34229634
PLoS One. 2023 Feb 16;18(2):e0281916
pubmed: 36795733
Eur J Public Health. 2017 Feb 1;27(1):173-178
pubmed: 28177503
Breast Cancer Res Treat. 2020 Dec;184(3):861-872
pubmed: 32875480
Lancet Glob Health. 2020 Sep;8(9):e1203-e1212
pubmed: 32827482
PLoS One. 2019 Nov 21;14(11):e0225039
pubmed: 31751359
World J Surg Oncol. 2018 Mar 22;16(1):63
pubmed: 29566711
N Engl J Med. 2014 Oct 2;371(14):1344-53
pubmed: 25265493
Breast Cancer Res Treat. 2021 Aug;189(1):285-296
pubmed: 34125339
J Clin Oncol. 2020 Oct 10;38(29):3439-3448
pubmed: 32783672
PLoS One. 2018 Feb 2;13(2):e0192071
pubmed: 29394271
Oncologist. 2022 Mar 11;27(3):e233-e243
pubmed: 35274708
Int J Cancer. 2014 Nov 1;135(9):2173-82
pubmed: 24658866
Oncologist. 2016 Jun;21(6):739-44
pubmed: 27091419
Int J Cancer. 2020 Oct 15;147(8):2131-2141
pubmed: 32306390
Int J Cancer. 2020 Jul 15;147(2):361-374
pubmed: 31600408
Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1666-72
pubmed: 26464428
Breast Cancer Res. 2023 Jan 23;25(1):7
pubmed: 36691057
Breast Cancer Res. 2019 Aug 13;21(1):93
pubmed: 31409419
S Afr Med J. 2014 May;104(5):380
pubmed: 25295329